[go: up one dir, main page]

AR059056A1 - Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia - Google Patents

Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia

Info

Publication number
AR059056A1
AR059056A1 ARP070100203A ARP070100203A AR059056A1 AR 059056 A1 AR059056 A1 AR 059056A1 AR P070100203 A ARP070100203 A AR P070100203A AR P070100203 A ARP070100203 A AR P070100203A AR 059056 A1 AR059056 A1 AR 059056A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
alkylene
ring
unsubstituted
Prior art date
Application number
ARP070100203A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR059056A1 publication Critical patent/AR059056A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Son utiles para el tratamiento de enfermedades, trastornos, o afecciones tales como síndrome metabolico y dislipidemia. Reivindicacion 1: Un compuesto de la formula (1) o una sal, solvato, éster, o tautomero farmacéuticamente aceptable del mismo, en donde: R1 está seleccionado del grupo que consiste en H, R4, haloalquilo, -alquilen-R4, -alquilen-R5, -alquilen-R6, alquenilo, alquinilo, y -alquilen-O-alquilo; R2 está seleccionado del grupo que consiste en alquilo, haloalquilo, -alquilen- R5, R4, R5, R6, R7 y -alquilen-O-R8; R3 está seleccionado del grupo que consiste en alquilo, haloalquilo, -alquilen-R5, R4, R5, R6, y R7; o R2 y R3 conjuntamente con el átomo de carbono al cual ellos están ambos unidos forman un anillo cicloalquilo o heterocicloalquilo, en donde dicho anillo cicloalquilo o heterocicloalquilo está sin sustituir o independientemente sustituido con uno o más grupos X5, y en donde dicho anillo cicloalquilo puede formar un compuesto espirocíclico con un segundo anillo cicloalquilo o con un anillo heterocicloalquilo, en donde el segundo anillo cicloalquilo o el anillo heterocicloalquilo está sin sustituir o independientemente sustituido con uno o más grupos X5; R4 es cicloalquilo no sustituido o cicloalquilo sustituido con uno o más grupos X1, R5 es arilo no sustituido y arilo sustituido con uno o más grupos X2; R6 está seleccionado del grupo que consiste en heteroarilo no sustituido y heteroarilo sustituido con uno o más grupos X3; R7 es heterocicloalquilo no sustituido y heterocicloalquilo sustituido con uno o más grupos X4, R8 está seleccionado del grupo que consiste en H, alquilo, R4, R5, R6, R7, -C(O)-alquilo, -C(O)-R5; cada R9 está independientemente seleccionado del grupo que consiste en H, alquilo, R4, R5, R6, y R7; R10 está seleccionado del grupo que consiste en R9, -C(O)-alquilo, y -C(O)-R5; Y es -O- o -N(R10)-; cada X1 está independientemente seleccionado del grupo que consiste en halogeno, alquilo, -O-alquilo, -OH, haloalquilo, arilo, y alquino; cada X2 está independientemente seleccionado del grupo que consiste en halogeno, alquilo, -O-alquilo, -OH, haloalquilo, arilo, y alquino; cada X3 está independientemente seleccionado del grupo que consiste en halogeno, alquilo, y N-oxido; cada X4 está independientemente seleccionado del grupo que consiste en alquilo, R5, -C(O)-alquilo, -C(O)-R5, -C(O)-O-alquilo, -alquilen-R5, R4, y -S(O2)-alquilo; y cada X5 está independientemente seleccionado del grupo que consiste en alquilo, un anillo arilo fusionado, -C(O)-alquilo, un anillo heteroarilo fusionado, -C(O)-O-alquilo, -C(O)-R5, -S(O2)-alquilo, -C(O)-N(R9)2, R5, R6, -C(O)-R4, -C(O)-O-R4, -S(O2)R4, -S(O2)-alquilen-R4, -S(O2)-alquilen-R5, -N(R9)-C(O)- O-alquilo, -N(R9)-C(O)-O-R4, -N(R9)-C(O)-N(R9)2 y -N(R9)2; en donde dicho anillo arilo fusionado de X5 está sin sustituir o independientemente sustituido con uno o más sustituyentes seleccionados de -alquilen-R7 o X2, y dicho anillo heteroarilo fusionado de X5 está sin sustituir o sustituido con uno o más grupos X3.
ARP070100203A 2006-01-20 2007-01-17 Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia AR059056A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76055506P 2006-01-20 2006-01-20

Publications (1)

Publication Number Publication Date
AR059056A1 true AR059056A1 (es) 2008-03-12

Family

ID=38190797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100203A AR059056A1 (es) 2006-01-20 2007-01-17 Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia

Country Status (14)

Country Link
US (1) US7763623B2 (es)
EP (1) EP1976854A2 (es)
JP (1) JP2009525961A (es)
KR (1) KR20080091814A (es)
CN (1) CN101400682A (es)
AR (1) AR059056A1 (es)
AU (1) AU2007208478A1 (es)
CA (1) CA2637717A1 (es)
IL (1) IL192907A0 (es)
MX (1) MX2008009413A (es)
PE (1) PE20070854A1 (es)
TW (1) TW200738729A (es)
WO (1) WO2007087204A2 (es)
ZA (1) ZA200806293B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1885726B1 (en) * 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR059056A1 (es) 2006-01-20 2008-03-12 Schering Corp Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
EP2297117B1 (en) 2008-05-19 2012-10-31 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
KR20120046188A (ko) * 2009-06-24 2012-05-09 뉴로크린 바이오사이언시즈 인코퍼레이티드 신규 화합물, 약제학적 조성물 및 이에 관련된 방법
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
TW201309639A (zh) 2011-02-17 2013-03-01 Lg Life Sciences Ltd 作為ｇｐｒ１１９促效劑之肟衍生物
US8865641B2 (en) * 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
WO2014164767A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
ES2665619T3 (es) 2013-03-14 2018-04-26 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent
WO2018053587A1 (en) * 2016-09-21 2018-03-29 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2826580A (en) 1958-03-11 Derivatives of y
DD263891A3 (de) 1986-12-23 1989-01-18 Dresden Arzneimittel Verbessertes verfahren zur herstellung von 2,4,6,8-tetrahydroxy-yrimido[5,4-d] pyrimidin und seinen salzen
DD265760A3 (de) 1987-05-25 1989-03-15 Dresden Arzneimittel Verfahren zur herstellung von 2,4,6,8-tetrachlorpyrimido-[5,4-d]pyrimidin
DE19624154A1 (de) 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US20040137563A9 (en) 1998-10-13 2004-07-15 Ruoping Chen Endogenous and non-endogenous versions of human G protein-coupled receptors
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
EP1377834A2 (en) 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
ATE466581T1 (de) 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
KR100772297B1 (ko) 2002-11-22 2007-11-02 니뽄 다바코 산교 가부시키가이샤 융합 비시클릭 질소-함유 헤테로사이클
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
SG157242A1 (en) * 2004-02-14 2009-12-29 Smithkline Beecham Corp Medicaments with hm74a receptor agonist activity
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20050251869A1 (en) 2004-05-04 2005-11-10 Tian-Quan Cai Animal model for raising HDL-cholesterol with niacin
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
KR20070070231A (ko) 2004-10-22 2007-07-03 스미스클라인 비참 코포레이션 Ｈｍ７４ａ 수용체 활성을 가지는 크산틴 유도체
CA2595477A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
JP2008538277A (ja) 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド 脂質関連障害の治療用の組成物および方法
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1885726B1 (en) 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20090117559A1 (en) 2005-08-10 2009-05-07 Liaw Chen W Methods for Determining Probability of an Adverse or Favorable Reaction to a Niacin Receptor Agonist
AU2006284926A1 (en) 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression
AR059056A1 (es) 2006-01-20 2008-03-12 Schering Corp Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
EP2158203A2 (en) 2007-04-13 2010-03-03 Schering Corporation Pyrimidinedione derivatives and use thereof

Also Published As

Publication number Publication date
AU2007208478A1 (en) 2007-08-02
TW200738729A (en) 2007-10-16
CN101400682A (zh) 2009-04-01
US20070173495A1 (en) 2007-07-26
WO2007087204A2 (en) 2007-08-02
CA2637717A1 (en) 2007-08-02
WO2007087204A3 (en) 2007-09-13
ZA200806293B (en) 2009-07-29
PE20070854A1 (es) 2007-09-10
MX2008009413A (es) 2008-10-01
EP1976854A2 (en) 2008-10-08
KR20080091814A (ko) 2008-10-14
JP2009525961A (ja) 2009-07-16
IL192907A0 (en) 2009-02-11
US7763623B2 (en) 2010-07-27

Similar Documents

Publication Publication Date Title
AR059056A1 (es) Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
AR053728A1 (es) Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos
RU2408584C2 (ru) Ингибиторы тирозинкиназы
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
AR074814A1 (es) Pirimidinas sustituidas como antagonistas del receptor ccr2 y usos de las mismas en medicamentos.
JP6486954B2 (ja) Ｂｔｋ阻害剤としてのピラゾール化合物
AR089019A1 (es) Derivados modificados de 4-fenil-piridina
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR069480A1 (es) Derivados de 2-amino-pirimidina
TW202221000A (zh) 用於降解ｅｇｆｒ之雙功能化合物及相關使用方法
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
AR070130A1 (es) Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
ES2653419T3 (es) Pirazolopirimidinilamino-indazoles sustituidos
AR078321A1 (es) Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)
EA201591078A1 (ru) Пептиды в качестве агонистов окситоцина
JP6403751B2 (ja) ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用
WO2014151630A2 (en) Compounds and compositions for the treatment of parasitic diseases
IL290745B2 (en) Pyrimidine compound and pharmaceutical use thereof
DK3059239T3 (en) SULFUL, BICYCLIC RELATIONSHIP
CA3043319A1 (en) Modulators of the 5-hydroxytryptamine receptor 7 and their method of use
BR112019024376A2 (pt) composto de fórmula geral (i), ou sais farmaceuticamente aceitáveis destes, composição farmacêutica e uso dos compostos ou sais farmaceuticamente aceitáveis destes
AR092555A1 (es) 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc
PE20120900A1 (es) Compuestos heterociclicos de fenoximetilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal